Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.
Bartalena
L
L
Section of Endocrinology, Department of Clinical Medicine, University of Insubria, Varese, Italy. l.bartalena@libero.it
Tanda
M L
ML
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000068800:Etanercept; D049970:Graves Ophthalmopathy / Q000628:therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007167:Immunotherapy; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000074323:Alemtuzumab; D000069283:Rituximab; D000068800:Etanercept